Anbio Biotechnology
Designs and distributes diagnostic products for laboratory, point-of-care, and home-use settings.
Something off on this page? Send us feedback.
Profile
Diagnostic products are designed across multiple testing platforms, made by outside manufacturers, and distributed for laboratory, point-of-care, and home-use settings. A single operating segment covers Europe, APAC, the Americas, and Africa.
Built around FIA, CLIA, RT-PCR, LFIA, LAMP, and Dry Chemistry, the in-vitro diagnostic product suite serves laboratory, point-of-care, and home-use settings. Products are designed internally, produced by original-equipment manufacturers, and distributed as finished diagnostics.
Commercial coverage spans Europe, APAC, the Americas, and Africa within a single operating segment. Research and development, product design, marketing, operations, and administration are shared across the suite, while product-sale revenue is generally recognized when control transfers at shipment.
All purchases are concentrated with two suppliers, and products are subject to health-care and product requirements in the jurisdictions where they are sold. Class B shares were structured to preserve holders’ voting influence.
Company facts
Key statistics
Year to date −74.3% · Average volume (30d) 126.4K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Apr 7, 2026 | — | $0.07 | — | — | $4.7M | — | −1.57% |
Financial highlights
| 7 quarters | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q3 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.0M | $6.3M | $2.5M | $5.0M | $2.0M | $4.7M | |
| Gross profit | $1.7M | $4.2M | $2.1M | $4.6M | $1.7M | $3.9M | |
| Operating income | $583.7K | $3.9M | −$1.7M | $3.7M | $1.2M | $2.8M | |
| Net income | $792.9K | $3.9M | −$1.3M | $4.1M | $1.3M | $3.0M | |
| Diluted EPS | $0.02 | $0.09 | −$0.03 | $0.09 | $0.03 | $0.07 | |
| Gross margin | 42.8% | 66.9% | 84.6% | 92.3% | 81.5% | 81.5% | |
| Operating margin | 14.8% | 61.5% | -68.6% | 73.4% | 59.1% | 59.1% |
Revenue by geography · FY25
Balance sheet, Dec 31, 2025Cash & short-term investments $11.9M · Total debt $0 · Total assets $30.2M · Shareholders' equity $30.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 43.89M · Float 39.69M · 90.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 25.8K | 0.06% | 13F | May 15, 2026 |
| BNP Paribas Arbitrage, SNC | 10.4K | 0.02% | 13F | May 12, 2026 |
| Morgan Stanley | 7.3K | 0.02% | 13F | May 15, 2026 |
| UBS Group AG | 6.3K | 0.01% | 13F | May 5, 2026 |
| Eversource Wealth Advisors, LLC | 266 | 0.00% | 13F | May 18, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Abbott
Broad IVD rival across laboratory, molecular, rapid and point-of-care testing
- Danaher
Global molecular-diagnostics rival through Cepheid
- QuidelOrtho
Direct rival in point-of-care and molecular diagnostics
- BD
Rival in clinical microbiology, molecular and rapid testing
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Anbio Biotechnology | $7.55 | −0.33% | $336.6M | 39.7 | — | 28.6 | — |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| QuidelOrtho | $14.70 | −0.27% | $1.01B | — | 17.5 | 0.4 | +2.6% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Median | 38.4 | 18.4 | 3.3 | +4.1% |